The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis

被引：0
|
作者：
Kongju Wu
Ming Yi
Shuang Qin
Qian Chu
Xinhua Zheng
Kongming Wu
机构：
[1] Medical School of Pingdingshan University,Department of Clinical Medicine
[2] Huazhong University of Science and Technology,Department of Oncology, Tongji Hospital of Tongji Medical College
来源：
Experimental Hematology & Oncology | / 8卷
关键词：
Immunotherapy; PD-1; PD-L1; CTLA-4; Immune checkpoint inhibitor; Combination therapy; Meta-analysis; Systematic review;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Impact of prophylactic TNF blockade in the dual PD-1 and CTLA-4 immunotherapy efficacy and toxicity
    Alvarez, Maite
    Otano, Itziar
    Minute, Luna
    Ochoa, Maria Carmen
    Perez-Ruiz, Elisabeth
    Melero, Ignacio
    Berraondo, Pedro
    CELL STRESS, 2019, 3 (07) : 236 - 239
  • [32] Meta-analysis of the efficacy and safety of PD-1/PD-L1 inhibitors administered alone or in combination with anti-VEGF agents in advanced hepatocellular carcinoma
    Feng, Zhichao
    Rong, Pengfei
    Wang, Wei
    GUT, 2020, 69 (10) : 1904 - 1906
  • [33] Assessment of the safety and efficacy of combination chemotherapy and PD-1/PD-L1 inhibitor treatment of breast cancer: A meta-analysis
    Qian, Da
    Xu, Yuhao
    Wu, Yihao
    Qiu, Jie
    Hong, Weimin
    Meng, Xuli
    CHINESE MEDICAL JOURNAL, 2023, 136 (14) : 1663 - 1670
  • [34] Efficacy and safety of PD-1 inhibitors for treating advanced melanoma: a systematic review and meta-analysis
    Li, Jing
    Gu, Jian
    IMMUNOTHERAPY, 2018, 10 (15) : 1293 - 1302
  • [35] The efficacy and safety of PD-1/PD-L1 inhibitors in breast cancer: a systematic review and meta-analysis
    Xiao, Bo-Ya
    Lin, Guo-He
    Zhao, Yan-Xia
    Wang, Bi-Cheng
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (06) : 3804 - 3818
  • [36] Clinical and molecular characteristics associated with the efficacy of PD-1/PD-L1 inhibitors for solid tumors: a meta-analysis
    Weng, Yi Ming
    Peng, Min
    Hu, Meng Xue
    Yao, Yi
    Song, Qi Bin
    ONCOTARGETS AND THERAPY, 2018, 11 : 7529 - 7542
  • [37] Response efficacy of PD-1 and PD-L1 inhibitors in salivary gland cancers: a systematic review and meta-analysis
    Babamohamadi, Zahra
    Taherkhani, Amirreza
    Yousefzadeh, Ali
    Moradi, Ali
    Heidari, Marziyeh
    Nasab, Zahra Sadat Hoseini
    Haghi, Seyedeh Mona
    Afkhami, Ayda
    Belbasi, Mohaddeseh
    Noroozi, Masoud
    Deravi, Niloofar
    FRONTIERS IN ONCOLOGY, 2025, 15
  • [38] Adverse Events of PD-1, PD-L1, CTLA-4, and LAG-3 Immune Checkpoint Inhibitors: An Analysis of the FDA Adverse Events Database
    Frey, Connor
    Etminan, Mahyar
    ANTIBODIES, 2024, 13 (03)
  • [39] Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1
    Assal, Amer
    Kaner, Justin
    Pendurti, Gopichand
    Zang, Xingxing
    IMMUNOTHERAPY, 2015, 7 (11) : 1169 - 1186
  • [40] Cardiovascular toxicity with CTLA-4 inhibitors in cancer patients: A meta-analysis
    Liu, Huiyi
    Fu, Lu
    Jin, Shuyu
    Ye, Xingdong
    Chen, Yanlin
    Pu, Sijia
    Xue, Yumei
    CANCER INNOVATION, 2024, 3 (03):
12345